Wto Agreement Pharmaceuticals

Posted by | October 17, 2021 | Uncategorized | No Comments

Governments sometimes apply special concessional tariff regimes for certain strategic products, such as. B the waiver of import duties on pharmaceutical or health-related products in order to improve access to them. It is reported that several countries (Krasovec and Connor, 1998) apply such tariff exemptions to public health products, particularly for non-profit buyers. As the U.S. appears to be on the verge of becoming the next major center of the COVID-19 pandemic, trade issues with China are hampering its ability to source products. In fact, just 10 days ago, President Trump complained that China had a “stranglehold” on U.S. supplies and concluded that China essentially had global control over global pharmaceuticals. But is this true? We have proposed here an analytical framework that links ten types of provisions of regional trade agreements with potential implications for four fundamental pharmaceutical policy objectives in several ways. We hope that this framework can prove useful for assessing the future impact on health and human rights and for researching the impact of trade agreements on pharmaceutical policy and access to medicines. The provisions of the TRIPS Plus Agreement may also affect prices and access through other mechanisms, such as. Β restrictions on compulsory licences and parallel imports, restrictions on the opposition and revocation of patents, restrictions excluding patentability and supplementary protection certificates. Although these types of provisions are included in other trade agreements (and some were originally proposed for the TPP), none of the four agreements reviewed contain such provisions in the final text.

Some trade agreements, including the TPP/CPTPP and the USMCA, also provide for countries to be members of the Patent Cooperation Treaty (PCT). PCT membership is likely to increase the volume of locally filed patent applications and, with the increasing workload of examiners, potentially increase the grant of patents that might otherwise be rejected, thereby increasing the likelihood that more drugs will have a single supplier. Since all members of the agreements discussed in this article are already members of the PCT, this particular provision will not change the current situation for them (although it may limit options for subsequent leaders). In general, when analyzing intellectual property provisions in trade agreements, it should be borne in mind that pct membership is required. Gleeson D, Menkes DM. Trade agreements and direct marketing of medicines to consumers. Int J Health Policy Manag. 2018;7(2):98–100. The rules in Chapter 15 of the CPTPP/CPTPP apply for the most part only to entities listed in a number of annexes. For most countries, the rules apply to all goods and services, except those that are explicitly excluded.


About admindrdejavu

Si deseas contactarme, no dudes en llamarme para agendar una reunion y conocer tu proyecto +52.8998.0143